Logo
  • About
    • What We Do
    • Team
    • Partners
  • Pipeline
  • Technologies
    • FastPharming®
    • Glycaneering™
    • LicKM
    • VLP
  • Resources
    • News
    • Events
    • Articles
    • Publications
  • Careers
  • Investors
  • Contact
  • Therapeutics
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-201 Subunit Vaccine
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • Factory Solutions
Investors

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
    • Presentations
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Data
    • Quote
    • Historical Data
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
Feb 16, 2021 4:05pm EST

iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update

Feb 16, 2021 8:00am EST

iBio Appoints Robert M. Lutz as Chief Financial & Business Officer

Feb 09, 2021 4:30pm EST

iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021

Dec 28, 2020 7:30am EST

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Dec 10, 2020 4:30pm EST

iBio Announces Closing of its Public Offering of Common Stock

Dec 08, 2020 8:55am EST

iBio Announces Pricing of $35 Million Public Offering of Common Stock

Dec 07, 2020 4:01pm EST

iBio Announces Proposed Public Offering of Common Stock

Dec 01, 2020 4:30pm EST

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

Nov 24, 2020 7:30am EST

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

Nov 16, 2020 4:05pm EST

iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …11
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Footer Logo
  • Therapeutics
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-201 Subunit Vaccine
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • Factory Solutions

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807

(979) 446-0027
LinkedIn
info@ibioinc.com
RSS News Feed

© 2021 iBio. All Rights Reserved.
Privacy Policy

  • About
  • Pipeline
  • Technologies
  • Resources
  • Careers
  • Investors
  • Contact